Doerfler P, Schoefmann N, Cabral G, Stuetz A, Wolff-Winiski B (2025)
Identification and characterization of AKR101 as potential new therapeutic for chronic wounds.
Oral presentation at the ETRS Annual Meeting 2025, Sept. 03-05, 2025, in Cardiff, UK
Wolff-Winiski B, Schoefmann N, Doerfler P, Cabral G, Stuetz A (2026)
Biological effects of AKR101, a potential new drug for chronic wound therapy.
Flash talk at the 55th Annual Conference of the European Society for Dermatological Research (ESDR)
September 09-12, 2026, Heidelberg, Germany
Schoefmann N, Cabral G, Doerfler P, Palla B, Etzold OW, Dupin D, Ågren MS, Burian EA, Plum F, Wolff-Winiski B (2026)
Bioactive inks as potential wound healing therapeutics: cellular responses in the presence of chronic wound exudates.
Poster at the 55th Annual Conference of the European Society for Dermatological Research (ESDR)
September 09-12, 2026, Heidelberg, Germany
Schoefmann N, Cabral G, Palla B, Etzold OW, Dupin D, Ågren MS, Burian EA, Kirketerp-Møller K, Ørts Pedersen S, Plum F, Svendsen J, Wolff-Winiski B (2026)
Efficacy of anti-inflammatory, anti-bacterial and pro-regenerative bioactive inks on fibroblast proliferation in the presence or absence of wound exudates.
Poster at the 36th Conference of the European wound Management Association, (EWMA - DEWU 2026)
May 06-08, 2026, Bremen, Germany
Cabral G, Schoefmann N, Doerfler P, Stuetz A, Wolff-Winiski B (2026)
Identification of AKR101 as potential new drug for chronic wound therapy.
Poster at the Meeting of the Wound Healing Society (WHS – SAWC)
April 8–11, 2026, Charlotte, NC, USA
Cabral G, Schoefmann N, Wolff-Winiski B (2025)
CHANGES IN THE PROTEOME INDICATE A SPECIFIC ROLE OF STAT-4 IN MEDIATING THE FIBROBLAST INFLAMMATORY RESPONSE TO CHRONIC WOUND EXUDATE.
Poster at the 35th Conference of the European Wound Management Association, the EWMA - GNEAUPP 2025 CONFERENCE, March 26-28, 2025, Barcelona, Spain
Wolff-Winiski B, Schoefmann N, Doerfler P, Cabral G, Stuetz A (2025)
Identification of AKR101 as potential new drug for chronic wound therapy.
Oral presentation at the 35th Conference of the European Wound Management Association, the EWMA - GNEAUPP 2025 CONFERENCE, March 26-28, 2025, Barcelona, Spain
Doerfler P, Schoefmann N, Stuetz A, Wolff-Winiski B (2022)
Development of a “theranostic” assay for chronic wounds and identification of compounds with so far unknown potential for treatment of chronic wounds
Oral presentation at the ÖGMBT 2022 Annual Meeting, Sept 19-22, 2022, in Vienna, Austria
Doerfler P, Schoefmann N, Cabral G, Stuetz A, Wolff-Winiski B (2024)
Identification and characterization of potential wound therapeutics based on a new personalized ex vivo wound model.
Poster at the ETRS-WHS-SKINTERM 2024 Annual Meeting, Sept. 24-27, 2024 in Amersfoort, Netherlands
Cabral G, Doerfler P, Schoefmann N, Stuetz A, Wolff-Winiski B (2023)
Development of personalized treatment for chronic wounds
Oral presentation at the ETRS 2022, Sept. 15-17, 2022, in Lyon, France